Puretech Health PLC Logo

Puretech Health PLC

ISIN

GB00BY2Z0H74

Ticker

PRTC

Sector

Health Care

Sub-Industry

Biotechnology

Country

United Kingdom

Year Founded

2005

About Puretech Health PLC

Company Description

Puretech Health PLC is a cutting-edge biotechnology company that is focused on developing and commercializing a wide range of innovative therapies in the healthcare industry. The company is based in the United Kingdom, and it has a growing presence in key markets around the world.

Puretech Health is dedicated to leveraging the latest scientific advances to create transformative medicines that improve human health and wellness. The company works closely with leading researchers, academic institutions, and industry partners to develop novel approaches to treating a wide range of medical conditions.

Headcount

111

Served Area

Worldwide

Headquarters

6 Tide St Ste 400
02210-2412, Boston
United Kingdom

Financial statements

Download as Excel
Line item in (usd) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A N/A 989,994,000.00 946,006,000.00 702,647,000.00
Noncurrent Assets N/A N/A 575,645,000.00 444,197,000.00 316,454,000.00
Property Plant And Equipment N/A N/A 22,777,000.00 26,771,000.00 22,957,000.00
Intangible Assets Other Than Goodwill N/A N/A 899,000.00 987,000.00 831,000.00
Investments In Associates N/A N/A 0.00 0.00 9,147,000.00
Noncurrent Receivables Due From Associates N/A N/A N/A 0.00 16,501,000.00
Noncurrent Financial Assets At Fair Value Through Profit Or Loss N/A N/A 530,161,000.00 397,179,000.00 251,892,000.00
Noncurrent Finance Lease Receivables N/A N/A 1,700,000.00 1,285,000.00 835,000.00
Other Noncurrent Assets N/A N/A 11,000.00 810,000.00 10,000.00
Current Assets N/A N/A 414,348,000.00 501,809,000.00 386,192,000.00
Trade And Other Current Receivables N/A N/A 2,558,000.00 3,174,000.00 11,867,000.00
Current Receivables Due From Associates N/A N/A 0.00 15,120,000.00 0.00
Current Prepaid Expenses N/A N/A 5,405,000.00 10,755,000.00 11,617,000.00
Current Tax Assets Current N/A N/A 0.00 4,514,000.00 10,040,000.00
Cash and cash equivalents 117,051,000.00 132,360,000.00 403,881,000.00 465,708,000.00 149,866,000.00
Current Finance Lease Receivables N/A N/A 381,000.00 415,000.00 450,000.00
Equity And Liabilities N/A N/A 989,994,000.00 946,006,000.00 702,647,000.00
Equity 167,971,000.00 650,398,000.00 653,539,000.00 584,147,000.00 547,589,000.00
Issued Capital N/A N/A 5,417,000.00 5,444,000.00 5,455,000.00
Retained Earnings N/A N/A 260,429,000.00 199,871,000.00 149,516,000.00
Share Premium N/A N/A 288,978,000.00 289,303,000.00 289,624,000.00
Treasury Shares N/A N/A N/A 0.00 26,492,000.00
Other Reserves N/A N/A -24,050,000.00 -40,077,000.00 -14,478,000.00
Merger Reserve N/A N/A 138,506,000.00 138,506,000.00 138,506,000.00
Equity Attributable To Owners Of Parent N/A N/A 669,748,000.00 593,515,000.00 542,220,000.00
Noncontrolling Interests N/A N/A -16,209,000.00 -9,368,000.00 5,369,000.00
Liabilities N/A N/A 336,455,000.00 361,859,000.00 155,057,000.00
Noncurrent Liabilities N/A N/A 155,531,000.00 135,725,000.00 58,172,000.00
Deferred Tax Liabilities N/A N/A 108,626,000.00 89,765,000.00 19,645,000.00
Longterm Borrowings N/A N/A 14,818,000.00 14,261,000.00 10,244,000.00
Current Liabilities N/A N/A 180,924,000.00 226,135,000.00 96,885,000.00
Trade And Other Current Payables N/A N/A 21,826,000.00 35,817,000.00 54,840,000.00
Current Contract Liabilities N/A N/A 1,472,000.00 65,000.00 2,185,000.00
Current Derivative Financial Liabilities N/A N/A 8,206,000.00 6,787,000.00 47,000.00
Other Current Liabilities N/A N/A 732,000.00 726,000.00 N/A
Line item in (usd) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 9,807,000.00 11,768,000.00 17,388,000.00 15,618,000.00
Revenue From Contracts With Customers 8,688,000.00 8,341,000.00 9,979,000.00 2,090,000.00
Other Income 672,167,000.00 178,732,000.00 159,983,000.00 N/A
Other Gains Losses 39,000.00 1,035,000.00 1,592,000.00 8,131,000.00
Profit Loss From Operating Activities -135,399,000.00 -119,531,000.00 -150,282,000.00 -197,807,000.00
Finance Income 4,362,000.00 1,183,000.00 214,000.00 5,799,000.00
Finance Costs 2,576,000.00 2,946,000.00 4,771,000.00 3,939,000.00
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method 30,791,000.00 -34,117,000.00 -73,703,000.00 -27,749,000.00
Profit Loss Before Tax 478,474,000.00 18,969,000.00 -58,953,000.00 -92,783,000.00
Income Tax Expense Continuing Operations 112,409,000.00 14,401,000.00 3,756,000.00 -55,719,000.00
Profit (loss) 366,065,000.00 4,568,000.00 -62,709,000.00 -37,065,000.00
Profit Loss Attributable To Owners Of Parent 421,144,000.00 5,985,000.00 -60,558,000.00 -50,354,000.00
Profit Loss Attributable To Noncontrolling Interests -55,079,000.00 -1,417,000.00 -2,151,000.00 13,290,000.00
Line item in (usd) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 366,065,000.00 4,568,000.00 -62,709,000.00 -37,065,000.00
Adjustments For Income Tax Expense N/A 112,077,000.00 14,402,000.00 3,756,000.00 -55,719,000.00
Adjustments For Finance Costs N/A 46,229,000.00 6,114,000.00 -5,050,000.00 N/A
Adjustments For Increase Decrease In Trade Account Payable N/A 11,166,000.00 605,000.00 8,338,000.00 22,033,000.00
Adjustments For Increase Decrease In Other Operating Payables N/A 3,002,000.00 -7,000.00 0.00 N/A
Adjustments For Depreciation And Amortisation Expense N/A 6,665,000.00 6,645,000.00 7,287,000.00 8,893,000.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss N/A N/A 0.00 0.00 8,390,000.00
Adjustments For Sharebased Payments N/A 14,468,000.00 10,718,000.00 13,950,000.00 14,698,000.00
Adjustments For Fair Value Gains Losses N/A 37,863,000.00 -232,674,000.00 -179,316,000.00 32,060,000.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets N/A 0.00 54,976,000.00 20,925,000.00 29,303,000.00
Interest Paid Classified As Operating Activities N/A 2,495,000.00 2,651,000.00 3,382,000.00 3,366,000.00
Interest Received Classified As Operating Activities N/A 3,648,000.00 1,155,000.00 214,000.00 3,460,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 0.00 20,737,000.00 27,766,000.00 20,696,000.00
Other Inflows Outflows Of Cash Classified As Operating Activities N/A 0.00 -7,000.00 -103,000.00 359,000.00
Cash Flows From Used In Operating Activities N/A -98,156,000.00 -131,827,000.00 -158,274,000.00 -178,792,000.00
Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A -16,036,000.00 0.00 0.00 N/A
Other Cash Receipts From Sales Of Equity Or Debt Instruments Of Other Entities Classified As Investing Activities N/A 9,294,000.00 350,586,000.00 218,125,000.00 118,710,000.00
Other Cash Payments To Acquire Equity Or Debt Instruments Of Other Entities Classified As Investing Activities N/A 1,556,000.00 1,150,000.00 500,000.00 5,000,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 0.00 0.00 30,000.00 0.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 12,138,000.00 5,170,000.00 5,571,000.00 2,176,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 400,000.00 254,000.00 90,000.00 0.00
Cash Flows From Used In Investing Activities N/A 63,659,000.00 364,478,000.00 197,375,000.00 -107,223,000.00
Payments From Changes In Ownership Interests In Subsidiaries N/A 0.00 0.00 806,000.00 0.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 1,678,000.00 2,908,000.00 3,375,000.00 4,025,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities N/A 0.00 0.00 -5,000.00 -41,000.00
Cash Flows From Used In Financing Activities N/A 49,910,000.00 38,869,000.00 22,727,000.00 -29,827,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A N/A 271,520,000.00 61,827,000.00 -315,842,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -104,000.00 0.00 0.00 N/A
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 15,309,000.00 271,520,000.00 61,827,000.00 N/A
Cash and cash equivalents 117,051,000.00 132,360,000.00 403,881,000.00 465,708,000.00 149,866,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2021 - Q4 English 🇬🇧

Capital Markets Information

ISIN

GB00BY2Z0H74

LEI

213800LVPDNO2Z9T9I39

Sub-Industry

Biotechnology

Listed Stock Exchange

London Stock Exchange

Stock Index

FTSE 250

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.